Lilly looks to double Japan business by 2020
This article was originally published in Scrip
Executive Summary
Lilly's global business might be facing challenges given the loss of exclusivity for the atypical antipsychotic Zyprexa (olanzapine) in most major markets, a major factor behind the US major's expectation of low single digit growth this year. But Japan remains one bright spot for the firm, which has had another strong sales increase in this key market and is aiming for a top 10 ranking there by the end of the decade.